Rallybio Corp
RLYB0.545USD
+0.010+1.83%
Horário de mercado （ET）Cotações atrasadas em 15 min
22.67MValor de mercado
PerdaP/L TTM
Mais detalhes de Rallybio Corp Empresa
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. It has two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Its other product candidates include RLYB114, RLYB331 and ENPP1 Program. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule with PK properties designed for the treatment of complement-mediated ophthalmic diseases. RLYB331 is for the treatment of severe anemia.
Informações da empresa
Código da empresaRLYB
Nome da EmpresaRallybio Corp
Data de listagemJul 29, 2021
CEODr. Stephen (Steve) Uden, M.D.
Número de funcionários25
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 29
Endereço234 Church Street
CidadeNEW HAVEN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal06510
Telefone12038593820
Sitehttps://rallybio.com/
Código da empresaRLYB
Data de listagemJul 29, 2021
CEODr. Stephen (Steve) Uden, M.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Stephen (Steve) Uden, M.D.
Dr. Stephen (Steve) Uden, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
730.36K
+1.56%
Ms. Paula Soteropoulos
Ms. Paula Soteropoulos
Independent Director
Independent Director
23.88K
--
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
14.24K
+184.74%
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Dr. Robert (Rob) Hopfner, Ph.D.
Dr. Robert (Rob) Hopfner, Ph.D.
Independent Director
Independent Director
--
--
Dr. Steven W. Ryder, M.D.
Dr. Steven W. Ryder, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Wendy K. Chung, M.D., Ph.D.
Dr. Wendy K. Chung, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Ronald M. (Ron) Hunt
Mr. Ronald M. (Ron) Hunt
Independent Director
Independent Director
--
--
Dr. Hui Liu, Ph.D.
Dr. Hui Liu, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lucian Iancovici, M.D.
Dr. Lucian Iancovici, M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Stephen (Steve) Uden, M.D.
Dr. Stephen (Steve) Uden, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
730.36K
+1.56%
Ms. Paula Soteropoulos
Ms. Paula Soteropoulos
Independent Director
Independent Director
23.88K
--
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
14.24K
+184.74%
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Dr. Robert (Rob) Hopfner, Ph.D.
Dr. Robert (Rob) Hopfner, Ph.D.
Independent Director
Independent Director
--
--
Dr. Steven W. Ryder, M.D.
Dr. Steven W. Ryder, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Detalhamento da receita
FY2024
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
636.00K
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qua, 2 de jul
Atualizado em: qua, 2 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Viking Global Investors LP
10.08%
Johnson & Johnson Innovation-JJDC, Inc.
8.74%
5AM Ventures
8.72%
New Leaf Venture Partners LLC
7.93%
TPG Capital, L.P.
7.28%
Other
57.25%
Investidores
Investidores
Proporção
Viking Global Investors LP
10.08%
Johnson & Johnson Innovation-JJDC, Inc.
8.74%
5AM Ventures
8.72%
New Leaf Venture Partners LLC
7.93%
TPG Capital, L.P.
7.28%
Other
57.25%
Tipos de investidores
Investidores
Proporção
Venture Capital
35.25%
Investment Advisor/Hedge Fund
15.11%
Investment Advisor
13.40%
Private Equity
7.28%
Individual Investor
4.16%
Hedge Fund
3.84%
Research Firm
0.25%
Pension Fund
0.03%
Other
20.68%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
146
33.40M
80.26%
-5.22M
2025Q1
153
34.13M
82.02%
-4.90M
2024Q4
156
33.77M
81.40%
-4.07M
2024Q3
163
33.31M
80.30%
-4.27M
2024Q2
165
34.52M
83.29%
-5.35M
2024Q1
149
33.11M
86.93%
-2.72M
2023Q4
143
34.47M
90.96%
-619.59K
2023Q3
138
35.89M
94.72%
-1.76M
2023Q2
134
36.21M
95.77%
-44.55K
2023Q1
130
35.24M
93.30%
-1.12M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Viking Global Investors LP
4.19M
10.08%
--
--
Mar 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
3.64M
8.74%
--
--
Mar 31, 2025
5AM Ventures
3.63M
8.72%
--
--
Mar 31, 2025
New Leaf Venture Partners LLC
3.30M
7.93%
--
--
Mar 31, 2025
TPG Capital, L.P.
3.03M
7.28%
--
--
Mar 31, 2025
Pivotal Bioventure Partners Investment Advisor LLC
2.40M
5.78%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
1.79M
4.29%
+18.52K
+1.05%
Mar 31, 2025
abrdn Inc.
1.73M
4.15%
--
--
Mar 31, 2025
Almitas Capital LLC
1.30M
3.13%
+2.46K
+0.19%
Mar 31, 2025
The Vanguard Group, Inc.
971.93K
2.34%
+46.41K
+5.01%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
DFA Dimensional US Core Equity Market ETF
0%
ProShares Hedge Replication ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Value ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 Covered Call ETF
0%
Ver Mais
DFA Dimensional US Core Equity Market ETF
Proporção0%
ProShares Hedge Replication ETF
Proporção0%
Dimensional US Core Equity 1 ETF
Proporção0%
iShares Micro-Cap ETF
Proporção0%
Global X Russell 2000 ETF
Proporção0%
iShares Russell 2000 Value ETF
Proporção0%
Proshares Ultra Russell 2000
Proporção0%
iShares Russell 2000 ETF
Proporção0%
ProShares UltraPro Russell2000
Proporção0%
Global X Russell 2000 Covered Call ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
